Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Władysław Sułowicz"'
Autor:
Ewa Ignacak, Dominik Cieniawski, Alina Bętkowska-Prokop, Czesław Osuch, Marek Kuźniewski, Władysław Sułowicz
Publikováno v:
BMC Nephrology, Vol 18, Iss 1, Pp 1-6 (2017)
Abstract Background Chronic refractory hypotension (IDH, intradialytic hypotension) is a rare but serious problem encountered in patients on hemodialysis. Patients with chronic hypotension are often disqualified by transplant teams from renal transpl
Externí odkaz:
https://doaj.org/article/5467f714d8524e16b40baceb2dbc5f89
Publikováno v:
Przegląd Dermatologiczny, Vol 98, Iss 3, Pp 239-246 (2011)
Introduction. Organ transplant recipients are at 10-fold higher risk ofdeveloping basal cell carcinoma and up to 250-fold higher risk of developingsquamous cell carcinoma compared with the general population.Common risk factors include the type of im
Externí odkaz:
https://doaj.org/article/357974607b0f4a9aba96e5db847d3c08
Autor:
Katarzyna Janda, Marcin Krzanowski, Mariusz Gajda, Paulina Dumnicka, Danuta Fedak, Grzegorz J. Lis, Piotr Jaśkowski, Jan A. Litwin, Władysław Sułowicz
Publikováno v:
International Journal of Endocrinology, Vol 2013 (2013)
Objective. The objective of the study was to assess the relationship between selected clinical and biochemical parameters of end stage renal disease (ESRD) patients and arterial calcification. Materials and Methods. The study comprised 59 stage 5 chr
Externí odkaz:
https://doaj.org/article/35193b3f373746b490cc20c03aadd249
Autor:
Ciro Esposito, Botond Csiky, Michael Schömig, Udaya Valluri, Jonathan Barratt, Władysław Sułowicz, Michael Reusch
Publikováno v:
Advances in Therapy
Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40cdc163721c176d6781c7c9a05a060f
https://doi.org/10.1007/s12325-021-01904-6
https://doi.org/10.1007/s12325-021-01904-6
Autor:
Ciro Esposito, James Young, Michael Schömig, Michael Reusch, Botond Csiky, Władysław Sułowicz, Jonathan Barratt
Publikováno v:
Advances in Therapy
Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods Efficacy and safety results from four phase 3, randomized, op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1629264b42b7ac68110f3f0d77dac9ef
https://doi.org/10.1007/s12325-021-01903-7
https://doi.org/10.1007/s12325-021-01903-7
Autor:
Ciro Esposito, Avtandil Tataradze, Udaya Valluri, Władysław Sułowicz, Michael Reusch, Evgeny Shutov, Nada Dimkovic, Branislav Andric
Publikováno v:
Nephrology Dialysis Transplantation
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3, multicenter, randomized, double-blind, placebo-controlled study examined p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e034519810f9ac7c5b4915699daf0418
https://doi.org/10.1093/ndt/gfab057
https://doi.org/10.1093/ndt/gfab057
Autor:
Nada Dimkovic, James Young, Elinor Cockburn, Jonathan Barratt, Władysław Sułowicz, Michael Reusch
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Randomised clinical trials evaluating anaemia correction using erythropoietin-stimulating agents (ESAs) in chronic kidney disease (CKD) patients have demonstrated an association between ESA use and increased risk of cardiovascular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eed29f34b71323b6fa08f3737af2ea1d
https://doi.org/10.1093/ndt/gfab085.003
https://doi.org/10.1093/ndt/gfab085.003
Autor:
Nada Dimkovic, Władysław Sułowicz, Christophe Mariat, Ciro Esposito, Evgeny Shutov, Michael Reusch, James Young, Jonathan Barratt
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, induces a coordinated erythropoietic response by increasing endogenous erythropoietin levels and improving iron metabolism. This analysis was performed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0005e82a6f0088b41bf689560743fd0c
https://doi.org/10.1093/ndt/gfab118.003
https://doi.org/10.1093/ndt/gfab118.003
Autor:
Władysław Sułowicz, Michael Reusch, Christophe Mariat, Ciro Esposito, Nada Dimkovic, James Young, Evgeny Shutov, Jonathan Barratt
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Roxadustat regulates erythropoiesis and iron metabolism through hypoxia-inducible factor prolyl hydroxylase inhibition. This regional analysis evaluated efficacy and safety for roxadustat versus placebo/darbepoetin alfa (DA) in ND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ef19a3a66a6266b6997edddf4906c34
https://doi.org/10.1093/ndt/gfab118.002
https://doi.org/10.1093/ndt/gfab118.002
Autor:
Marek Kuźniewski, Władysław Sułowicz, Ewa Ignacak, Dominik Cieniawski, Alina Bętkowska-Prokop, Joanna Sułowicz
Introduction After kidney transplantation (KTx) in patients with diagnosed cancers, calcineurin inhibitor tacrolimus (TAC) is replaced by sirolimus or everolimus (EV). Objective The objective of the study was to compare the lipid metabolism parameter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a234ae0a541bb6cf165f083944f3cf
https://ruj.uj.edu.pl/xmlui/handle/item/263516
https://ruj.uj.edu.pl/xmlui/handle/item/263516
